CORRECTION



Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Keren Jia¹⁺, Yang Chen¹⁺, Yu Sun², Yajie Hu², Lei Jiao³, Jie Ma³, Jiajia Yuan¹, Changsong Qi¹, Yanyan Li¹, Jifang Gong¹, Jing Gao⁴, Xiaotian Zhang¹, Jian Li¹, Cheng Zhang^{1*} and Lin Shen^{1*}

Correction: BMC Medicine 20, 223 (2022) https://doi.org/10.1186/s12916-022-02421-1

The original article [1] contains numerical errors in the following sentence regarding median irOS:

'Additionally, CLDN18.2-positive group had shorter OS and irOS than CLDN18.2-negative group (median OS: 23.33 vs.36.6 months, P < 0.001; median irOS: 10.03 vs. 20.13 months, P = 0.044, respectively).'

The sentence should instead read as follows:

'Additionally, CLDN18.2-positive group had shorter OS and irOS than CLDN18.2-negative group (median

[†]Keren Jia and Yang Chen contributed equally.

The original article can be found online at https://doi.org/10.1186/s12916-022-02421-1.

*Correspondence: Cheng Zhang qenya_z@bjmu.edu.cn Lin Shen shenlin@bjmu.edu.cn ¹ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China ² Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China ³ Panovue Biotechnology (Beijing) Co, Ltd, Beijing, China ⁴ National Cancer Center/National Clinical Research Center for Cancer/

Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ficenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

OS: 23.33 vs.36.6 months, P < 0.001; median irOS: 9.27 vs. 12.83 months, P = 0.044, respectively)."

Published online: 29 September 2023

Reference

1. Jia K, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Medicine. 2022;20:223. https://doi.org/10.1186/ s12916-022-02421-1.